The principal activity of the group is to develop immune-based therapies. The group develops these therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition the group is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection. The group has developed an immune-based therapy to induce specific immune responses for the treatment of HIV. The group is developing complementary technology combining two platform technologies cytokines and tumor cell lines to develop cancer vaccines to treat colon, brain, prostate and melanoma cancers.
